Cagrilintide, developed as AM833, is an investigational long-acting amylin analog. It matters partly on its own and largely because of its combination with semaglutide — a co-formulation known as CagriSema, developed on the premise that two different satiety pathways combined outperform either alone.
This guide situates Cagrilintide within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.
What is cagrilintide?
Cagrilintide is a synthetic analog of amylin, a 37-amino-acid hormone co-secreted with insulin by pancreatic beta cells. Native amylin has a very short half-life and an unhelpful tendency to aggregate, which is why it is not usable as a drug in its natural form.
Cagrilintide is engineered for stability and a long duration supporting weekly subcutaneous dosing. It is investigational and not FDA-approved. It should not be confused with pramlintide, an approved short-acting amylin analog used quite differently.
How amylin signaling works
Amylin is released alongside insulin in response to eating and acts principally in the hindbrain, at the area postrema, to promote satiation. It also slows gastric emptying and suppresses inappropriate post-meal glucagon secretion.
The key point for combination therapy is that amylin and GLP-1 act through distinct receptors and distinct central circuits, even though both ultimately reduce food intake. That non-overlapping mechanism is the rationale for pairing them: rather than pushing one pathway harder and paying for it in dose-limiting nausea, the strategy recruits a second pathway to add effect.
What the evidence shows
As monotherapy, cagrilintide produced dose-dependent weight reduction in phase 2 work, establishing that a long-acting amylin analog is an active weight-management agent in its own right.
The more consequential data concern the combination with semaglutide, studied in the phase 3 REDEFINE program. The combination has produced weight reductions greater than either component alone, supporting the two-pathway hypothesis. As with any investigational combination, the headline numbers require care: results vary by dose, duration, population and how completers are handled, and cross-trial comparison against other agents is unreliable.
Gastrointestinal adverse effects, nausea in particular, remain the principal tolerability consideration, as they are across this entire therapeutic area.
Regulatory status
Cagrilintide is not approved by the FDA, alone or in combination. It is not an established compounding substance, and material sold under this name outside a clinical trial is not a legitimate pharmaceutical supply.
For clinicians, the value in understanding it now is conceptual. Amylin represents a genuinely different lever from the incretin pathway that dominates current practice, and combination approaches targeting multiple satiety circuits are the clear direction of the field. Our peptide formulary tracks where each agent actually sits.
Learn peptides the right way
Empire Medical Training's Peptide Therapy Master Course is a CME-accredited program covering incretin and amylin satiety physiology, patient selection, monitoring, regulatory status, and compliant sourcing — taught by board-certified physicians. Available in person and via livestream. It is also Course 1 of Empire’s Peptide Therapy Certification, which adds business, marketing and healthcare-law training, a documented case series and a final exam.
Explore the Certification →